research use only
Cat.No.S1661
|
In vitro |
DMSO
: 50 mg/mL
(198.23 mM)
Water : 2 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 252.22 | Formula | C11H12N2O5 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 61135-33-9 | -- | Storage of Stock Solutions |
|
|
| Synonyms | 5-EdU, 2'-Deoxy-5-ethynyluridine | Smiles | C#CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O | ||
| In vivo |
5-Ethynyl-2'-deoxyuridine (EdU, 5-EdU, 2'-Deoxy-5-ethynyluridine), a thymidine analogue developed for detection of DNA synthesis, was found to slightly increase the number of its positive cells in the dentate gyrus of the hippocampus (DG) in a dose dependent manner in voluntary exercise (running) mouse groups, while significantly decreasing in restraint stress mouse model. |
References |
|
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06271200 | Not yet recruiting | Metabolic Syndrome |
National Health Research Institutes Taiwan|Tri-Service General Hospital|Chang Gung Memorial Hospital|National Taiwan University Hospital Hsin-Chu Branch|Taichung Armed Forces General Hospital |
February 20 2024 | Not Applicable |
| NCT05923944 | Not yet recruiting | Anxiety|Anxiety Disorders and Symptoms |
School of Health Sciences Geneva|University of Geneva Switzerland|University of Haifa|Swiss National Science Foundation |
January 2024 | Not Applicable |
| NCT05599191 | Recruiting | Refractory Chronic Cough |
Bellus Health Inc. - a GSK company |
October 25 2022 | Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.